Oxford Biomedica Past Earnings Performance
Past criteria checks 0/6
Oxford Biomedica's earnings have been declining at an average annual rate of -33.2%, while the Biotechs industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 3.5% per year.
Key information
-33.22%
Earnings growth rate
-32.18%
EPS growth rate
| Biotechs Industry Growth | 11.51% |
| Revenue growth rate | 3.46% |
| Return on equity | -33.55% |
| Net Margin | -17.85% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
Narrative Update • Jun 04
OXB: Future Upside Will Rely On Fast Track And New APAC Agreement
Analysts have nudged their fair value estimate for Oxford Biomedica slightly lower to £8.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E. Recent Street research resuming coverage has reinforced the broader analytical focus on the stock.Narrative Update • May 20
OXB: Future Upside Will Depend On Fast Track Execution Success
Analysts have adjusted their price target on Oxford Biomedica to reflect updated assumptions on discount rate, revenue growth, profit margins and future P/E. The latest Street research has resumed coverage with a supportive stance on the stock and its long term value potential around £8.43.
Narrative Update • May 03
OXB: Future Cash Generation And Execution Risks Will Shape Balanced Outlook
Analysts have lifted their price target on Oxford Biomedica to £5.50, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that support a more refined view of the stock’s risk and earnings profile. Analyst Commentary Recent research coverage frames Oxford Biomedica as an opportunity with a refreshed risk and earnings profile, but not all commentary is uniformly positive.Narrative Update • Apr 19
OXB: Future Performance Will Reflect Fast Track Platform Execution Success
Analysts have lifted their price target for Oxford Biomedica from £6.67 to £8.43, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that align with recent Street research support. Analyst Commentary Bullish Takeaways Bullish analysts see the resumed coverage as a sign that Oxford Biomedica is now better aligned with current sector assumptions on revenue growth and profitability, which feeds directly into the higher fair value estimate.
Narrative Update • Apr 04
OXB: Post Transition Buy Ratings Will Support Higher Quality Business Perception
Analysts have increased the updated fair value estimate for Oxford Biomedica from £9.50 to £11.70 per share, citing recent Buy ratings and higher price targets that reflect expectations for a higher quality business following the company’s transition. Analyst Commentary Recent research indicates that bullish analysts are becoming more constructive on Oxford Biomedica, with fresh Buy ratings and higher price objectives supporting the updated fair value estimate.Narrative Update • Mar 21
OXB: Upgraded Rating Will Likely Expose Transition Risks In Execution
Analysts have raised their price target for Oxford Biomedica to £7.35 from £3.80. They cite the company's transition to what they view as a higher quality business as a key driver for the change.Narrative Update • Mar 06
OXB: Higher Rating Will Likely Magnify Execution And Funding Risks
Analysts have lifted their price target on Oxford Biomedica from £3.80 to £7.35, citing a higher quality business profile following the company's transition and reflecting this in updated fair value, discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary The latest research points to a clearer view of Oxford Biomedica's equity story, with a higher price target of 735 GBp set alongside the view that the business profile has improved following its transition.Narrative Update • Feb 20
OXB: Transition Progress And Buy Rating Will Support Higher Perceived Business Quality
Analysts have modestly trimmed their fair value estimate for Oxford Biomedica from £9.70 to £9.50, citing updated assumptions on discount rates, margins and future P/E. Some now see a higher quality business that supports a Buy rating and a higher £7.35 price target on the shares.Narrative Update • Feb 06
OXB: Upgraded Rating Will Likely Expose Vulnerable Execution Assumptions
Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business following the company's transition and reflecting modest tweaks to the discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E multiple. Analyst Commentary Recent research points to a business that analysts view as higher quality following Oxford Biomedica's transition, with the new £7.35 price target reflecting updated assumptions on discount rate, revenue and margin profiles, and a revised future P/E multiple.Narrative Update • Jan 23
OXB: Upgraded Outlook Will Likely Expose Fragile Profitability Assumptions
Analysts have lifted their price target on Oxford Biomedica to £7.35 from £3.80, citing a higher quality business mix after the company’s transition and updated assumptions around revenue growth, profit margins and future P/E. Analyst Commentary Recent research highlights a shift in how the market is framing Oxford Biomedica.Narrative Update • Jan 09
OXB: Transition Progress Will Drive Rerated Business Quality And Higher Confidence
Analysts lifted their price target on Oxford Biomedica to £7.35 from £3.80 after updating their fair value estimate and assumptions on the discount rate, revenue growth, profit margin and future P/E, reflecting increased confidence in the company’s transition and business quality. Analyst Commentary Recent research shows a clear shift in sentiment toward Oxford Biomedica, with bullish analysts pointing to a higher-quality business profile following the company’s transition.Analysis Article • Dec 30
Revenues Working Against Oxford Biomedica plc's (LON:OXB) Share Price
With a price-to-sales (or "P/S") ratio of 4.9x Oxford Biomedica plc ( LON:OXB ) may be sending bullish signals at the...Narrative Update • Dec 25
OXB: Higher Price Outlook Will Likely Expose Execution And Margin Weakness
Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting improved growth expectations despite a slightly higher discount rate and modestly lower projected profit margins. Analyst Commentary While the latest target price increase signals confidence in Oxford Biomedica's long term prospects, some Bearish analysts continue to flag risks around execution, profitability, and valuation.Narrative Update • Dec 11
OXB: Future Performance Will Reflect US Capacity Expansion And Margin Execution Risks
Analysts have raised their price target on Oxford Biomedica to 970 GBp from 930 GBp, reflecting slightly stronger expectations for long term revenue growth and profit margins, while maintaining a broadly similar valuation multiple outlook. Analyst Commentary Analysts describe the higher price target as a reflection of improving confidence in Oxford Biomedica's ability to scale its revenue base and gradually enhance operating leverage, while still acknowledging execution risks in a competitive cell and gene therapy landscape.Narrative Update • Nov 27
OXB: Future Performance Will Balance Revenue Momentum With Margin Execution Risks
Narrative Update on Oxford Biomedica Analysts have raised their price target for Oxford Biomedica by £0.55 to £6.48. This change reflects improved profit margin expectations and is reinforced by recent optimistic research updates.Narrative Update • Sep 13
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Analysts have raised Oxford Biomedica’s price target from £5.55 to £5.93, citing improved growth prospects, commercial execution, and operational strength, with ongoing share price weakness seen as a potential entry point despite lingering market uncertainties and execution risks. Analyst Commentary Bullish analysts cite an improved growth outlook and enhanced commercial execution as key drivers for the upward price target revision.Analysis Article • Sep 12
Investors Still Aren't Entirely Convinced By Oxford Biomedica plc's (LON:OXB) Revenues Despite 35% Price Jump
Oxford Biomedica plc ( LON:OXB ) shares have continued their recent momentum with a 35% gain in the last month alone...Narrative Update • Aug 27
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Analysts have raised Oxford Biomedica’s price target from £5.08 to £5.40, citing strong commercial execution and improving fundamentals despite some concerns over market visibility and client demand. Analyst Commentary Bullish analysts highlight Oxford Biomedica’s strong commercial track record and operational excellence as underpinning their positive outlook.Analysis Article • Jul 29
Oxford Biomedica plc's (LON:OXB) Price Is Right But Growth Is Lacking After Shares Rocket 30%
Despite an already strong run, Oxford Biomedica plc ( LON:OXB ) shares have been powering on, with a gain of 30% in the...New Narrative • May 09
CDMO Expansion Will Widen Global Cell And Gene Therapy Access
Expansion into AAV and other vector types reduces dependency risks and supports earnings growth through diversified revenue streams.Analysis Article • Apr 10
Health Check: How Prudently Does Oxford Biomedica (LON:OXB) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Feb 28
Oxford Biomedica plc (LON:OXB) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...Analysis Article • Oct 19
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 23
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
The Oxford Biomedica plc ( LON:OXB ) share price has fared very poorly over the last month, falling by a substantial...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Oxford Biomedica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 169 | -30 | 93 | 5 |
| 30 Sep 25 | 160 | -34 | 94 | 5 |
| 30 Jun 25 | 151 | -37 | 94 | 4 |
| 31 Mar 25 | 140 | -40 | 93 | 4 |
| 31 Dec 24 | 129 | -43 | 93 | 5 |
| 30 Sep 24 | 113 | -93 | 124 | -22 |
| 30 Jun 24 | 97 | -142 | 155 | -48 |
| 31 Mar 24 | 93 | -150 | 136 | -18 |
| 31 Dec 23 | 90 | -157 | 117 | 11 |
| 30 Sep 23 | 104 | -110 | 71 | 64 |
| 30 Jun 23 | 119 | -62 | 25 | 117 |
| 31 Mar 23 | 130 | -50 | 24 | 106 |
| 31 Dec 22 | 140 | -39 | 23 | 95 |
| 30 Sep 22 | 133 | -32 | 21 | 82 |
| 30 Jun 22 | 126 | -25 | 19 | 69 |
| 31 Mar 22 | 134 | -3 | 17 | 58 |
| 31 Dec 21 | 143 | 19 | 14 | 47 |
| 30 Sep 21 | 139 | 19 | 13 | 41 |
| 30 Jun 21 | 135 | 19 | 13 | 34 |
| 31 Mar 21 | 111 | 6 | 12 | 37 |
| 31 Dec 20 | 88 | -6 | 11 | 40 |
| 30 Sep 20 | 77 | -9 | 12 | 39 |
| 30 Jun 20 | 66 | -13 | 13 | 38 |
| 31 Mar 20 | 65 | -14 | 12 | 34 |
| 31 Dec 19 | 64 | -16 | 12 | 30 |
| 30 Sep 19 | 64 | -12 | 10 | 26 |
| 30 Jun 19 | 64 | -8 | 9 | 22 |
| 31 Mar 19 | 65 | 0 | 8 | 20 |
| 31 Dec 18 | 67 | 8 | 7 | 19 |
| 30 Sep 18 | 62 | 4 | 7 | 22 |
| 30 Jun 18 | 57 | 0 | 7 | 25 |
| 31 Mar 18 | 47 | -5 | 7 | 23 |
| 31 Dec 17 | 38 | -9 | 7 | 22 |
| 30 Sep 17 | 34 | -10 | 6 | 22 |
| 30 Jun 17 | 31 | -11 | 5 | 22 |
| 31 Mar 17 | 29 | -14 | 6 | 23 |
| 31 Dec 16 | 28 | -17 | 6 | 24 |
| 30 Sep 16 | 26 | -16 | 7 | 24 |
| 30 Jun 16 | 24 | -16 | 8 | 24 |
| 31 Mar 16 | 20 | -15 | 7 | 22 |
| 31 Dec 15 | 16 | -13 | 7 | 20 |
| 30 Sep 15 | 15 | -12 | 6 | 20 |
| 30 Jun 15 | 13 | -10 | 5 | 19 |
Quality Earnings: OXB is currently unprofitable.
Growing Profit Margin: OXB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OXB is unprofitable, and losses have increased over the past 5 years at a rate of 33.2% per year.
Accelerating Growth: Unable to compare OXB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.2%).
Return on Equity
High ROE: OXB has a negative Return on Equity (-33.55%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 21:49 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oxford Biomedica plc is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kane Slutzkin | Deutsche Bank |
| Susie Jana | Edison Investment Research |
| Jens Lindqvist | Investec Bank plc (UK) |